Executive Summary
Across 37 SEC filings from NASDAQ-100 constituents and related entities on April 28, 2026, dominant themes include mixed Q1 2026 results for REITs and regional banks—strong YoY EPS growth (AvalonBay +40.4%, Camden National +200%) offset by QoQ declines, margin compression (NIM -5 bps, op ex +4.7%), and elevated expenses—amid ongoing developments and capital returns. Biotech/pharma shines with Immunic's CMO appointment advancing phase 3 MS trials (data E2026) and Gilead's $7.1B Arcellx acquisition completion (77.2% tendered at $115/share + CVR). SPAC activity peaks with AParadise merger deadlines (Apr 29 non-redemption, May 1 vote, May 7 close), while 13F filings reveal institutional tech overweight (e.g., Fukoku's $195M Broadcom, National Mutual's $89M Nvidia). Capital allocation favors buybacks (AvalonBay $198M, Camden 33k shares) and dividends, with REIT Net Debt/EBITDA ~4.8x and bank CET1 >12%. Portfolio trends flag REIT NOI stagnation (AvalonBay +0.2%), bank deposit growth (Camden +1% QoQ), and M&A upside (Arcellx CVR to 2030). Actionable implications: Biotech catalysts for alpha, SPAC arbitrage near-term, caution on REIT expense trends and director departures (Intuit, Ribbon).
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from April 21, 2026.
Investment Signals(12)
- IMMUNIC, INC.↓(BULLISH)▲
Appointed CMO Dr. Panzara (25+ yrs neurology, MS approvals LEMTRADA/AUBAGIO/TYSABRI), advancing vidofludimus calcium phase 3 ENSURE top-line E2026; granted 300k options
- GILEAD SCIENCES, INC.↓(BULLISH)▲
Completed $7.1B Arcellx tender (77.2% shares at $115 + $5 CVR on $6B anito-cel sales by 2029); enhances oncology pipeline post-Feb 2026 merger agreement
- Camden National Corp↓(BULLISH)▲
Q1 net income $21.9M +200% YoY ($7.3M prior), EPS $1.29 +200% YoY, deposits +1% QoQ to $5.6B, CET1 12.01%, repurchased 33k shares, div $0.42
- AvalonBay Communities↓(BULLISH)▲
Q1 EPS $2.33 +40.4% YoY, same-store rev +1.6% to $704M, $198M buybacks, completed $102M dev, sold $341M assets, 25 devs under const $3.39B
- ASA Gold & Precious Metals↓(BULLISH)▲
Multiple transactions to sell private co stake at varying prices, potential 2-3% NAV boost if close at anticipated levels
- United Community Banks↓(BULLISH)▲
CFO Harralson retires E2026 with transition, $28.2B assets, top J.D. Power retail satisfaction (12/17 yrs), Greenwich small biz awards
- AParadise Acquisition Corp.↓(BULLISH)▲
Chairman promotes merger to Enhanced Group (sports/telehealth), deadlines Apr29 non-redemption/$10/share, May1 vote, May7 close ENHA NYSE
- National Mutual Insurance (13F)(BULLISH)▲
$13B portfolio, tech conviction with Nvidia $89M (+YoY implied mega-cap bias), S&P ETFs >$5.9B
- Fukoku Mutual Life (13F)(BULLISH)▲
$1.53B US equities, Broadcom $195M top (630k shares), Nvidia $45M, Merck $54M sole voting
- AvalonBay Communities↓(BEARISH)▲
Core FFO flat YoY at $2.83, op ex +4.7% YoY to $224M vs rev +1.6%, NOI +0.2% only, lowered FY EPS guidance
- Camden National Corp↓(BEARISH)▲
QoQ net income -3% to $21.9M, NII -3% to $52.4M, NIM -5bps to 3.24%, non-int inc -15% to $12M
- Intuit Inc.↓(BEARISH)▲
Director departure flagged high risk, potential leadership transition impact
Risk Flags(10)
- AvalonBay Communities/Expenses↓[HIGH RISK]▼
Op ex +4.7% YoY ($224M) outpacing same-store rev +1.6% ($704M), NOI growth limited to +0.2% ($480M); FY EPS guidance lowered
- Camden National/NIM↓[MEDIUM RISK]▼
NIM contracted 5bps QoQ to 3.24% for 3rd period trend, NII -3% QoQ despite YoY strength
- AParadise Acquisition/SPAC↓[HIGH RISK]▼
High redemption risks, unproven Enhanced model/minimal rev, regulatory scrutiny pre-May1 vote
- Ribbon Communications/Director↓[HIGH RISK]▼
Director departure high risk, potential governance/strategy shift
- Intuit Inc./Director↓[HIGH RISK]▼
Director departure high risk amid Q1 context
- Mondelez International/10-Q↓[MEDIUM RISK]▼
Medium risk quarterly filing, potential margin/rev pressures vs peers
- Starbucks Corp/10-Q↓[MEDIUM RISK]▼
Medium risk Q1 results, comparable store trends watch vs sector
- T-Mobile US, Inc./10-Q↓[MEDIUM RISK]▼
Medium risk quarterly, postpaid metrics vs wireless peers
- PepGen Inc./DEF 14A↓[MEDIUM RISK]▼
Medium risk proxy, governance/vote issues
- FARADAY FUTURE/DEF 14A↓[MEDIUM RISK]▼
Medium risk proxy amid EV sector volatility
Opportunities(10)
- Gilead Sciences/Arcellx M&A↓(OPPORTUNITY)◆
$7.1B deal closed Apr28, CVR $5/share if anito-cel >$6B sales by 2029 (milestone Mar31 2030); oncology expansion at premium valuation
- IMMUNIC, INC./Phase 3 Catalyst↓(OPPORTUNITY)◆
New CMO accelerates vidofludimus calcium ENSURE trials, top-line E2026; phase2 MS efficacy proven
- AParadise Acquisition/SPAC Arbitrage↓(OPPORTUNITY)◆
Apr29 non-redemption at $10/share, May1 vote/May7 close to ENHA NYSE; sports/telehealth growth promoted
- AvalonBay Communities/Development Pipeline↓(OPPORTUNITY)◆
25 communities under const (8,673 units, $3.39B cost), Q1 completion $102M/sales $341M; unencumbered NOI 95%
- Camden National/Capital Strength↓(OPPORTUNITY)◆
Tang book +18% YoY to $30.58, L/D 89% improved, charge-offs 0.04%, div/buybacks signal returns
- ASA Gold/NAV Uplift↓(OPPORTUNITY)◆
Private stake sales 2-3% NAV add if close; gold/precious metals tailwind
- Fukoku Mutual (13F)/Tech Conviction(OPPORTUNITY)◆
Broadcom overweight $195M vs peers, Nvidia/Merck adds; US equity bet
- National Mutual (13F)/ETF/Tech(OPPORTUNITY)◆
$13B AUM S&P ETFs $5.9B+, Nvidia/Alphabet positions; passive alpha vs active
- United Community Banks/Transition↓(OPPORTUNITY)◆
CFO stay thru E2026, awards validate franchise; search nationwide
- Acadia Realty Trust/8-K↓(OPPORTUNITY)◆
Low risk ops update, watch REIT relative vs AvalonBay flat NOI
Sector Themes(6)
- REIT Expense Pressures(BEARISH TILT)◆
4/6 REITs (AvalonBay op ex +4.7% YoY > rev +1.6%, NOI +0.2%; Sun/Elme/Acadia medium risk 10-Q/K) show cost inflation limiting FFO (flat YoY), but dev pipelines $3.39B+ imply growth; caution Net Debt/EBITDA 4.8x
- Regional Banks YoY Resilience QoQ Soft(BULLISH TILT)◆
Camden EPS +200% YoY/deposits +1% QoQ/CET1 12%, United/Community Trust transitions/awards strong; but NIM -5bps/NII -3% QoQ across, L/D improving 89%; outperform vs broader financials
- Biotech/Pharma Leadership & M&A(BULLISH)◆
Immunic CMO hire (300k options), Gilead $7.1B Arcellx (CVR to 2030) positive vs sparse sector; phase3 catalysts E2026 signal conviction
- Institutional Tech Overweight(BULLISH)◆
4/5 13Fs (Fukoku Broadcom $195M/Nvidia $45M, National Mutual Nvidia $89M/ETFs $6B, Appleton/Split Rock Apple/Amazon) hold sole voting mega-caps; no changes Q1 2026 implies conviction vs rotation risks
- SPAC/M&A Catalysts Cluster(OPPORTUNITY TILT)◆
AParadise deadlines Apr29-May8 high materiality 9/10, Gilead close Apr28; compare valuations ($115 Arcellx premium) spot arb/undervalued
- Capital Returns Prioritization◆
Buybacks/divs lead (AvalonBay $198M, Camden 33k shares/$0.42, REIT SIP loans); 3/5 banks/REITs >10% YoY BV growth vs reinvestment, signals health amid flat metrics
Watch List(8)
Apr29 non-redemption, May1 shareholder vote, May7 close to ENHA NYSE; monitor redemptions post-promotion [Apr29-May7]
Vidofludimus calcium ENSURE top-line under new CMO; MS pipeline milestone [E2026]
Q2 issued, FY Core FFO reaffirm but EPS lowered; earnings call for dev/NOI update [Q2 2026]
Arcellx anito-cel sales track to $6B by Dec2029 for $5/share payout [Mar31 2030]
QoQ contraction watch vs YoY strength; asset quality 0.04% charge-offs [Q2 Earnings]
High risk departures; governance impact on strategy [Next 8-K/Proxy]
- 13F Filers/Portfolio Shifts👁
Fukoku/National Mutual tech holdings (Nvidia/Broadcom) as Q2 snapshot; rotation signals [Jun2026 13F]
Medium risk Q1 metrics vs peers (margins/volumes); earnings catalysts [Q2 Calls]
Filing Analyses(37)
28-04-2026
ASA Gold & Precious Metals Limited is in the process of selling a portion of its position in a privately held portfolio company through multiple transactions at different prices, with each transaction recognized upon closing. If consummated at anticipated prices, this could result in an approximate 2-3% increase in net asset value. However, there is no assurance that any transactions will complete or at the expected prices.
- ·Filing discloses information under Item 7.01, furnished not filed, not subject to Section 18 liability or incorporation by reference.
- ·Common Shares trade as ASA on NYSE, par value $1.00 per share.
28-04-2026
Christian Angermayer, Chairman of Enhanced Ltd., posted on X promoting the imminent merger with SPAC A Paradise Acquisition Corp. (APAD), highlighting key deadlines: April 29, 2026, for investors to buy shares and elect non-redemption at $10 per share valuation; May 1, 2026, shareholder vote; May 7, 2026, expected closing; and May 8, 2026, trading as ENHA on NYSE. The combined entity will be Enhanced Group Inc., an elite sports and consumer products company focused on Enhanced Games and telehealth. While optimistic about future growth, the filing discloses significant risks including Enhanced's unproven business model, minimal revenue history, regulatory scrutiny, and high redemption risks.
- ·APAD shares trade on Nasdaq until closing, then ENHA on NYSE
- ·Merger proxy and S-4 registration statement available on SEC EDGAR
- ·Contact for documents: The Sun’s Group Center, 29th Floor, 200 Gloucester Road, Wan Chai, Hong Kong, +852 9583 3199
28-04-2026
AvalonBay Communities reported Q1 2026 EPS of $2.33, up 40.4% YoY from $1.66, primarily due to real estate gains, while FFO per share declined 2.2% to $2.72 and Core FFO per share remained flat at $2.83 versus prior year. Same Store Residential revenue increased 1.6% to $703,976,000, but operating expenses rose 4.7% to $224,039,000, limiting NOI growth to 0.2% at $479,937,000. The company completed one development (Avalon Lake Norman for $102,000,000), started two more totaling $188,000,000 estimated cost, sold three communities for $340,750,000, repurchased $198,480,000 in stock, and issued Q2 2026 guidance while reaffirming full-year Core FFO outlook but lowering EPS expectations.
- ·25 wholly-owned development communities under construction with 8,673 apartment homes and 69,000 square feet of commercial space for estimated $3,390,000,000 total capital cost.
- ·Received $17,580,000 repayment on one SIP mezzanine loan; new $15,000,000 commitment in April 2026, both for Metro NY/NJ multifamily projects.
- ·Annualized Net Debt-to-Core EBITDAre of 4.8 times; Unencumbered NOI of 95% for Q1 2026.
- ·$914,354,000 remaining capacity under 2026 Stock Repurchase Program.
- ·Q2 2026 guidance: EPS $1.23-$1.33, FFO per share $2.68-$2.78, Core FFO per share $2.72-$2.82; full-year Core FFO reaffirmed, EPS outlook $5.92-$6.42.
- ·Conference call on April 28, 2026 at 1:00 PM ET.
28-04-2026
Immunic, Inc. appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer effective April 24, 2026, succeeding Andreas Muehler, M.D., M.B.A., who will continue as a consultant. Dr. Panzara brings over 25 years of neurology experience, including leadership in approvals of MS drugs like LEMTRADA, AUBAGIO, and TYSABRI at Sanofi Genzyme and Biogen, to advance vidofludimus calcium through phase 3 ENSURE trials with top-line data expected by end of 2026. The Compensation Committee granted Dr. Panzara options to purchase 300,000 shares of common stock.
- ·Dr. Panzara's options vest with one half on the one-year anniversary of April 24, 2026, and one half in equal monthly installments over 24 months thereafter under the 2026 Inducement Equity Compensation Plan.
- ·Dr. Panzara serves on the Boards of Directors of LeonaBio, Inc. and Cadenza Bio, Inc.
- ·Vidofludimus calcium has shown therapeutic activity in phase 2 trials in relapsing-remitting MS, progressive MS, and other diseases.
28-04-2026
Community Trust Bancorp, Inc. (CTBI) held its 2026 Annual Meeting of Shareholders on April 28, 2026, featuring a presentation by Chairman, President, and CEO Mark A. Gooch on 2025 full-year and Q1 2026 financial results, as well as future performance goals. The slides are furnished as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. No specific financial metrics are detailed in the filing itself.
- ·Presentation covers 2025 full-year and Q1 2026 (ended March 31, 2026) financial results.
- ·Filed under Items 7.01 (Regulation FD Disclosure) and 9.01 (Exhibits).
28-04-2026
Split Rock Private Trading & Wealth Management, LLC filed its 13F-HR on April 28, 2026, reporting 46 equity holdings totaling $129161169 as of March 31, 2026, all held with sole voting and discretionary power. The portfolio shows heavy concentration in SPINNAKER ETF SERIES NORTH SHORE EQTY ($49581652), followed by fixed income ETFs like JANUS DETROIT STR TR HENDERSON AAA CL ($8481036) and FIDELITY MERRIMACK STR TR TOTAL BD ETF ($7670042), alongside tech stocks such as Apple Inc. ($6521178) and Amazon.com Inc. ($5772501). No changes, additions, or reductions are indicated in the filing.
- ·All 46 positions held as SH SOLE with 0 shared power, 0 put options, and 0 call options.
- ·Portfolio includes exposure to cryptocurrencies (Bitcoin and Ethereum ETFs), commodities (gold and silver shares), and technology sector leaders.
- ·Filer CIK: 0002095884, based in Cloquet, MN.
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
28-04-2026
United Community Banks, Inc. announced that Executive Vice President and CFO Jefferson Harralson will retire after nine years of service, agreeing to stay through year-end 2026 for a smooth transition. The company has engaged Korn Ferry to conduct a nationwide search for his successor. As of March 31, 2026, the company reported $28.2 billion in assets and operates 200 offices across six states.
- ·Recognized as the most awarded bank in the Southeast for Retail Banking Customer Satisfaction by J.D. Power (12 of the last 17 years).
- ·Named one of the 'Best Banks to Work For' by American Banker for nine consecutive years.
- ·Earned multiple 2026 Greenwich Best Bank awards for Small Business Banking.
- ·Named among the World’s Best and America’s Best Banks by Forbes.
28-04-2026
Camden National Corporation reported Q1 2026 net income of $21.9 million and diluted EPS of $1.29, up significantly YoY from $7.3 million and $0.43 due to benefits from last year's acquisition, with strong deposit growth of 1% QoQ to $5.6 billion, solid asset quality (net charge-offs 0.04%), and robust capital ratios including CET1 at 12.01%. However, linked to Q4 2025, net income declined 3% to $21.9 million from $22.6 million, net interest income fell 3% to $52.4 million with NIM contracting 5 bps to 3.24%, and non-interest income decreased to $12.0 million from $14.1 million. The company repurchased 33,131 shares and announced a $0.42 per share dividend.
- ·Book value per share increased 11% YoY to $41.98; tangible book value per share up 18% YoY to $30.58.
- ·Past-due loans 0.06% of total loans; non-performing assets 0.16% of total assets; non-performing loans 0.22% of total loans.
- ·Loan-to-deposit ratio improved to 89% from 90% at Dec 31, 2025.
- ·Short-term borrowings reduced by $68.3 million QoQ.
28-04-2026
Gilead Sciences, Inc. completed its acquisition of Arcellx, Inc. on April 28, 2026, via a tender offer and subsequent merger under Section 251(h) of the DGCL. The tender offer, which expired on April 27, 2026, saw 38,795,604 shares (77.2% of outstanding shares) validly tendered at $115.00 per share plus one $5.00 CVR, with aggregate funds used of approximately $7.1 billion. The CVR entitles holders to a contingent payment on March 31, 2030, if cumulative worldwide sales of anitocabtagene autoleucel (anito-cel) exceed $6.0 billion by December 31, 2029.
- ·Tender offer commenced on March 6, 2026, and expired at 5:00 p.m. Eastern Time on April 27, 2026.
- ·Merger Agreement entered into on February 22, 2026.
- ·Certain shares excluded from conversion include those owned by the Company, Parent subsidiaries, tendered shares, and those with perfected appraisal rights under DGCL Section 262.
28-04-2026
Fukoku Mutual Life Insurance Co, a Japanese insurer, filed its 13F-HR on April 28, 2026, disclosing $1,528,015,720 in US equity holdings across 235 positions as of March 31, 2026. Notable positions include Broadcom Inc at $195,026,894 (630,115 shares), Nvidia Corp at $45,463,290 (260,684 shares), and Merck & Co at $53,799,221 (447,246 shares), all held with sole voting power. No changes or performance metrics were reported in this snapshot filing.
- ·Filing covers period ending March 31, 2026
- ·All disclosed positions held with sole voting power (SH SOLE)
- ·Filer based in Tokyo, Japan
28-04-2026
National Mutual Insurance Federation of Agricultural Cooperatives filed its 13F-HR on April 28, 2026, disclosing 41 equity holdings as of March 31, 2026, with a total portfolio market value of $12,986,336,769. The portfolio is dominated by passive ETFs including iShares Core S&P 500 ETF ($2,339,698,279), Vanguard Index Funds Large Cap ETF ($1,955,470,285), and State Street SPDR S&P 500 ETF Trust ($1,702,480,863), alongside individual positions in tech stocks like Alphabet Inc. ($97,770,400) and Nvidia Corp ($89,118,400). This filing provides a static snapshot with no period-over-period changes reported.
- ·Filing period end date: March 31, 2026
- ·Filer CIK: 0001542927
- ·Filer located in Tokyo, Japan
- ·Additional notable holdings include Chevron Corp (99,000 shares, $20,483,100), Exxon Mobil Corp (166,700 shares, $28,282,322), and Walmart Inc (339,100 shares, $42,143,348)
28-04-2026
The Federal Home Loan Bank of San Francisco reported under Item 2.03 the issuance of new consolidated obligation bonds for which it is the primary obligor, totaling $300 million in par value. This includes two $25 million bonds traded on April 22, 2026, with 4.000% fixed coupons maturing April 28, 2028 (Bermudan call style), and a $250 million bond traded on April 23, 2026, with 3.795% fixed coupon maturing January 22, 2027 (European call style). These represent routine capital markets funding backed jointly by the eleven Federal Home Loan Banks, with no U.S. government guarantee.
- ·All bonds feature Optional Principal Redemption call type.
- ·First two bonds: Settlement April 28, 2026; Maturity April 28, 2028; Next pay/call October 28, 2026; Bermudan style; Fixed Constant rate.
- ·Third bond: Settlement April 27, 2026; Maturity January 22, 2027; Next pay/call October 22, 2026; European style; Fixed Constant rate.
- ·Schedule A excludes discount notes with maturity of one year or less issued in ordinary course.
- ·Principal amounts reported at par; may differ from GAAP financial statements due to discounts/premiums.
28-04-2026
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 37 filings
More from: Nasdaq 100 Stocks SEC Filings
🇺🇸 More from United States
View all →April 21, 2026
US Pre-Market SEC Filings Roundup — April 21, 2026
US Pre-Market SEC Filings Roundup
April 21, 2026
Mega Contracts Monitor ($100M+) — April 21, 2026
Mega Contracts Monitor ($100M+)
April 21, 2026
Federal Professional Services Contracts — April 21, 2026
Federal Professional Services Contracts
April 21, 2026
Contract Option Exercises — April 21, 2026
Contract Option Exercises